FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

New, longer-acting treatment offers option to reduce the frequency of injections for children with growth hormone deficiency from daily to once-weekly

Related Keywords

United States ,Japan ,Australia ,Canada ,Phillip Frost ,Joel Steelman ,Angela Hwang ,Cook Children Health Care System ,National Organization For Rare Disorders ,Exchange Commission ,Outcomes Research ,Pfizer ,Pfizer Inc ,Nasdaq ,Drug Administration ,Health Inc ,Youtube ,Linkedin ,Clinical Program ,Chief Commercial Officer ,Global Biopharmaceuticals Business ,Pediatric Endocrinologist ,Cook Children ,Health Care ,Chief Executive Officer ,Prescribing Information ,Prader Willi Syndrome ,Idiopathic Short Stature ,Turner Syndrome ,Gestational Age ,Chronic Renal ,Change Patient Lives ,Annual Report ,Looking Information ,Factors That May Affect Future ,Growth Hormone ,Accessed February ,Opin Endocrinol Diabetes ,Patient Centered Outcomes ,South Dartmouth ,Markets ,